CUMBERLAND PHARMACEUTICALS (CPIX) Fundamental Analysis & Valuation

NASDAQ:CPIX • US2307701092

Current stock price

3.09 USD
-0.02 (-0.64%)
Last:

This CPIX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CPIX Profitability Analysis

1.1 Basic Checks

  • CPIX had positive earnings in the past year.
  • In the past year CPIX had a positive cash flow from operations.
  • CPIX had negative earnings in each of the past 5 years.
  • CPIX had a positive operating cash flow in 4 of the past 5 years.
CPIX Yearly Net Income VS EBIT VS OCF VS FCFCPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

  • With a decent Return On Assets value of -3.69%, CPIX is doing good in the industry, outperforming 73.44% of the companies in the same industry.
  • CPIX has a better Return On Equity (-11.40%) than 72.92% of its industry peers.
Industry RankSector Rank
ROA -3.69%
ROE -11.4%
ROIC N/A
ROA(3y)-6.65%
ROA(5y)-6.02%
ROE(3y)-20.32%
ROE(5y)-16.9%
ROIC(3y)N/A
ROIC(5y)N/A
CPIX Yearly ROA, ROE, ROICCPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20 -25

1.3 Margins

  • CPIX's Gross Margin of 85.02% is amongst the best of the industry. CPIX outperforms 86.98% of its industry peers.
  • In the last couple of years the Gross Margin of CPIX has grown nicely.
  • CPIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.27%
GM growth 5Y1.89%
CPIX Yearly Profit, Operating, Gross MarginsCPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CPIX Health Analysis

2.1 Basic Checks

  • CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CPIX has more shares outstanding than it did 1 year ago.
  • CPIX has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CPIX has an improved debt to assets ratio.
CPIX Yearly Shares OutstandingCPIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
CPIX Yearly Total Debt VS Total AssetsCPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 0.51, we must say that CPIX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.51, CPIX is in line with its industry, outperforming 51.04% of the companies in the same industry.
  • The Debt to FCF ratio of CPIX is 1.10, which is an excellent value as it means it would take CPIX, only 1.10 years of fcf income to pay off all of its debts.
  • CPIX's Debt to FCF ratio of 1.10 is amongst the best of the industry. CPIX outperforms 95.31% of its industry peers.
  • CPIX has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.21, CPIX is in line with its industry, outperforming 44.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 1.1
Altman-Z 0.51
ROIC/WACCN/A
WACC8.82%
CPIX Yearly LT Debt VS Equity VS FCFCPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M

2.3 Liquidity

  • CPIX has a Current Ratio of 1.01. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.01, CPIX is doing worse than 84.38% of the companies in the same industry.
  • A Quick Ratio of 0.84 indicates that CPIX may have some problems paying its short term obligations.
  • The Quick ratio of CPIX (0.84) is worse than 80.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.84
CPIX Yearly Current Assets VS Current LiabilitesCPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CPIX Growth Analysis

3.1 Past

  • CPIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 237.50%, which is quite impressive.
  • The Earnings Per Share has been decreasing by -1.73% on average over the past years.
  • CPIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.57%.
  • Measured over the past years, CPIX shows a small growth in Revenue. The Revenue has been growing by 3.53% on average per year.
EPS 1Y (TTM)237.5%
EPS 3YN/A
EPS 5Y-1.73%
EPS Q2Q%50%
Revenue 1Y (TTM)17.57%
Revenue growth 3Y1.95%
Revenue growth 5Y3.53%
Sales Q2Q%31.03%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CPIX Yearly Revenue VS EstimatesCPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
CPIX Yearly EPS VS EstimatesCPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2023 2024 2025 0 0.2 -0.2

More info and screens

Find the best growth stocksShow best growing peers

3

4. CPIX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 28.09 indicates a quite expensive valuation of CPIX.
  • 79.17% of the companies in the same industry are more expensive than CPIX, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of CPIX to the average of the S&P500 Index (26.91), we can say CPIX is valued inline with the index average.
Industry RankSector Rank
PE 28.09
Fwd PE N/A
CPIX Price Earnings VS Forward Price EarningsCPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CPIX is valued a bit cheaper than the industry average as 77.60% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPIX indicates a rather cheap valuation: CPIX is cheaper than 91.67% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.73
EV/EBITDA 29.8
CPIX Per share dataCPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPIX Dividend Analysis

5.1 Amount

  • CPIX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPIX Fundamentals: All Metrics, Ratios and Statistics

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (4/10/2026, 4:30:01 PM)

3.09

-0.02 (-0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners17.64%
Inst Owner Change0%
Ins Owners3.54%
Ins Owner Change0.12%
Market Cap46.23M
Revenue(TTM)44.52M
Net Income(TTM)-2.84M
Analysts43.33
Price TargetN/A
Short Float %1.7%
Short Ratio0.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 28.09
Fwd PE N/A
P/S 1.04
P/FCF 9.73
P/OCF 9.37
P/B 1.86
P/tB 4.65
EV/EBITDA 29.8
EPS(TTM)0.11
EY3.56%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.32
FCFY10.28%
OCF(TTM)0.33
OCFY10.67%
SpS2.98
BVpS1.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.03
Profitability
Industry RankSector Rank
ROA -3.69%
ROE -11.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.02%
FCFM 10.67%
ROA(3y)-6.65%
ROA(5y)-6.02%
ROE(3y)-20.32%
ROE(5y)-16.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.27%
GM growth 5Y1.89%
F-Score7
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 1.1
Debt/EBITDA 3.87
Cap/Depr 4.4%
Cap/Sales 0.41%
Interest Coverage N/A
Cash Conversion 364.51%
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 0.84
Altman-Z 0.51
F-Score7
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)5.75%
Cap/Depr(5y)12.77%
Cap/Sales(3y)0.68%
Cap/Sales(5y)1.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)237.5%
EPS 3YN/A
EPS 5Y-1.73%
EPS Q2Q%50%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.57%
Revenue growth 3Y1.95%
Revenue growth 5Y3.53%
Sales Q2Q%31.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y699.85%
FCF growth 3Y-9.36%
FCF growth 5Y7.49%
OCF growth 1Y905.7%
OCF growth 3Y-16.44%
OCF growth 5Y-1.87%

CUMBERLAND PHARMACEUTICALS / CPIX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CUMBERLAND PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 3 / 10 to CPIX.


Can you provide the valuation status for CUMBERLAND PHARMACEUTICALS?

ChartMill assigns a valuation rating of 3 / 10 to CUMBERLAND PHARMACEUTICALS (CPIX). This can be considered as Overvalued.


Can you provide the profitability details for CUMBERLAND PHARMACEUTICALS?

CUMBERLAND PHARMACEUTICALS (CPIX) has a profitability rating of 3 / 10.


What is the valuation of CUMBERLAND PHARMACEUTICALS based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CUMBERLAND PHARMACEUTICALS (CPIX) is 28.09 and the Price/Book (PB) ratio is 1.86.